Dr. Rebecca Daniels Kush is President of Catalysis, Inc., a consulting company founded in 1997 with a vision to apply enterprising solutions to transform clinical research and accelerate a learning health system. She is also the Chief Innovation Officer for Elligo Health Research, which is dedicated to engaging physicians and patients who may not otherwise have access to research and transforming the research process using eSource and improved data flow techniques.
Rebecca also consults for the Translational Research Informatics Institute (TRI Japan), working to expand the International Academic Research Organization (IARO) Council activities globally. She serves on the Steering Committee of the Learning Health Community.
Previously, Rebecca was the Founder, President, and CEO of the Clinical Data Interchange Standards Consortium (CDISC). This organization offers a suite of data standards that support clinical research in therapeutic areas that affect more than 1.5 billion lives. These standards are now required for submissions for new drug applications by the FDA and PMDA.
Rebecca has more than 30 years of experience in clinical research, including positions within academia and at the U.S. National Institutes of Health, a global CRO, and biopharmaceutical companies in the U.S. and Japan.
She wrote the chapter on Data Sharing in Clinical Research Informatics (ed., Springer), was the lead author of eClinical Trials: Planning and Implementation (a CenterWatch publication), and has written numerous publications for journals like the New England Journal of Medicine and Science Translational Medicine. She is currently an Associate Editor for Wiley’s open access journal on Learning Health Systems.
Rebecca earned her Doctorate in Physiology and Pharmacology from the University of California San Diego (UCSD) School of Medicine, and her Bachelor of Science degree in Biology and Chemistry from the University of New Mexico.